ABSTRACT
Since the outbreak of COVID-19, severe acute respiratory syndrome coronavirus 2 genome is still mutating, forming a variety of variants with strong transmission capacity, causing the spread of the epidemic worldwide, posing a serious threat to people's physical and mental health, and posing a major challenge to global public health. Omicron remains the main variant in several outbreaks worldwide, accounting for about 99% of the global genetic sequence. Recently, the World Health Organization announced that the subvariant of Omicron BA.5 has been found in more than 100 countries and regions around the world, causing the global epidemic rebound. However, there are few studies on the subvariant BA.5. This article reviews the latest research progress in epidemiology, infectivity, pathogenicity, vaccine and monoclonal antibody protection against Omicron subvariant BA.5, in order to provide reference for scientific prevention and control of Omicron subvariant BA.5.
ABSTRACT
The outbreak of COVID-19 caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) in 2019 threatens global public health. In the early stage, respiratory symptoms are the most common in patients with new coronal pneumonia, but with the spread of the disease around the world, gastrointestinal symptoms such as diarrhea, nausea and vomiting have attracted more and more attention. And some patients take diarrhea as the first symptom, which is easy to cause missed diagnosis. This paper expounds the close relationship between COVID-19 and gastrointestinal tract, and reviews the research progress of COVID-19's effect on gastrointestinal tract.